Intravascular ultrasound developer Endosonics broke ground thisweek on a new manufacturing facility in Rancho Cordova, CA. ThePleasanton, CA, vendor said that strong demand for its productsnecessitated the construction of the 44,000-square-foot
Intravascular ultrasound developer Endosonics broke ground thisweek on a new manufacturing facility in Rancho Cordova, CA. ThePleasanton, CA, vendor said that strong demand for its productsnecessitated the construction of the 44,000-square-foot facility,which will manufacture the company's Oracle and Five-64 catheters.Endosonics will continue to produce its current line of cathetersin Pleasanton.
In other news, Endosonics reported last month that its CardioVascularDynamics (CVD) subsidiary has signed an agreement with the vascularintervention group of Guidant to develop new perfusion angioplastycatheters. Guidant last year received an option for CVD's mechanicalangioplasty catheter (MAC) technology, and last month's agreementexercises that option.
As part of the deal, Guidant granted CVD exclusive rights tomarket Guidant's SmartNeedle products, which use Doppler ultrasound-guidedneedle technology to locate and access arteries and veins in patients.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.